Concurrent palliative chemoradiation leads to survival and quality of life benefits in poor prognosis stage III non-small-cell lung cancer: A randomised trial by the Norwegian Lung Cancer Study Group

British Journal of Cancer

Volumn 109, Issue 6, 2013, Pages 1467-1475

  Strom H H ^a,b   Bremnes, R M ^b,c   Sundstrom S H ^d   Helbekkmo, N ^c   Flotten ^e   Aasebo U ^b,c  

^a Helgeland Hospital   (Norway)

^b UNIVERSITY OF TROMSØ   (Norway)

^c UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

^d TRONDHEIM UNIVERSITY HOSPITAL   (Norway)

^e HAUKELAND UNIVERSITY HOSPITAL   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN;

AGED; ARTICLE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER PALLIATIVE THERAPY; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CHEMORADIOTHERAPY; CONTROLLED STUDY; FEMALE; HUMAN; INTERMETHOD COMPARISON; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; NORWAY; OPEN STUDY; OVERALL SURVIVAL; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; QUALITY OF LIFE; RADIATION DOSE; RADIATION DOSE FRACTIONATION; RANDOMIZED CONTROLLED TRIAL; SURVIVAL RATE; TREATMENT DURATION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CHEMORADIOTHERAPY; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; NORWAY; PALLIATIVE CARE; PROGNOSIS; QUALITY OF LIFE; SURVIVAL ANALYSIS; VINBLASTINE;

EID: 84884590948     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/bjc.2013.466     Document Type: Article

References (45)

1. Atagi S, Kawahara M, Yokoyama A, Okamoto H, Yamamot N, Ohe Y, Sawa T, Ishikura S, Shibata T, Fukuda H (2012) Thoracic radiotherapy with or without daily low-dose carboplatin in elderly patients with non-small-cell lung cancer: A randomised, controlled, phase 3 trial by the Japan Clinical Oncology Group (JCOG0301). Lancet Oncol 13: 671-678.
2. Baggstrom MQ, Waqar SN, Sezhiyan AK, Gilstrap E, Gao F, Morgensztern D, Govindan R (2011) Barriers to enrollment in non-small cell lung cancer therapeutic clinical trials. J Thorac Oncol 6: 98-102.
3. Barbera L, Bezjak A (2013) Have we forgotten that radiation is an effective therapy for lung cancer? J Thorac Oncol 8: 4-5.
4. Blackstock AW, Govindan R (2007) Definitive chemoradiation for the treatment of locally advanced non small-cell lung cancer. J Clin Oncol 25: 4146-4152.
5. Blanco JAG, Toste IS, Alvarez RF, Cuadrado GR, Gonzalvez AM, Martin IJG (2008) Age, comorbidity, treatment decision and prognosis in lung cancer. Age Ageing 37: 715-718.
6. Brundage M, Osoba D, Bezjak A, Tu D, Palmer M, Pater J. National Cancer Institute of Canada Clinical Trials Group (2007) Lessons learned in the assessment of health-related quality of life: Selected examples from the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 5078-5081.
7. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E (1989) Carboplatin dosage: Prospective evaluation of a simple formula based on renal function. J Clin Oncol 7: 1748-1756.
8. Cancer Registry of Norway (2011) Cancer in Norway 2009. Special issue: Cancer Screening in Norway, In: Haldorsen T (eds). Cancer Registry of Norway: Oslo.
9. Claassens L, van Meerbeeck J, Coens C, Quinten C, Ghislain I, Sloan EK, Wang XS, Velikova G, Bottomley A (2011) Health-related quality of life in non-small-cell lung cancer: An update of a systematic review on methodologic issues in randomized controlled trials. J Clin Oncol 29: 2104-2120.
10. Crino L, Weder W, van Meerbeeck J, Felip E. ESMO Guidelines Working Group 2010 Early stage and locally advanced (non-metastatic) nonsmall- cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Ann Oncol 21(Suppl 5 v103-v115.
11. Davies AM, Chansky K, Lau DHM, Leigh BR, Gaspar LE, Weiss GR, Wozniak AJ, Crowley JJ, Gandara DR. SWOG S9712 (2006) Phase II study of consolidation paclitaxel after concurrent chemoradiation in poor-risk stage III non-small-cell lung cancer: SWOG S9712. J Clin Oncol 24: 5242-5246.
12. De Rijke JM, Schouten LJ, ten Velde GPM, Wanders SL, Bollen ECM, Lalisang RI, Van Dijck JAAM, Kramer GWP, Van Den Brandt PA (2004) Influence of age, comorbidity and performance status on the choice of treatment for patients with non-small cell lung cancer; results of a population-based study. Lung Cancer 46: 233-245.
13. Fayers P, Aaronson N, Bjordal K, Groenvold M, Curran D, Bottomley A. on behalf of the EORTC QOL Group. (2001) The EORTC QLQ-C30 scoring manual (ed 3). European Organisation for Research and Treatment of Cancer: Brussels, Belgium
14. Fayers P, Bottomley A. EORTC Quality of Life Group, Quality of Life Unit (2002) Quality of life research within the EORTC-the EORTC QLQ-C30. European Organisation for Research and Treatment of Cancer. Eur J Cancer 38(Suppl 4): S125-S133.
15. Fournel P, Robinet G, Thomas P, Souquet P-J, Léna H, Vergnenégre A, Delhoume J-Y, Le Treut J, Silvani J-A, Dansin E, Bozonnat M-C, Daurés J-P, Mornex F, Pérol M. Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francis de Pneumo-Cancérologie (2005) Randomized phase III trial of sequential chemoradiotherapy compared with concurrent chemoradiotherapy in locally advanced non-small-cell lung cancer: Groupe Lyon-Saint-Etienne d'Oncologie Thoracique-Groupe Francis de Pneumo-Cancérologie NPC 95-01 Study. J Clin Oncol 23: 5910-5917.
16. Gronberg BH, Bremnes RM, Flotten O, Amundsen T, Brunsvig PF, Hjelde HH, Kaasa S, Plessen Von C, Stornes F, Tollali T, Wammer F, Aasebo U, Sundstrom S (2009) Phase iii study by the Norwegian lung cancer study group: Pemetrexed plus carboplatin compared with gemcitabine plus carboplatin as first-line chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 27: 3217-3224.
17. Helbekkmo N, Sundstrøm SH, Aasebo U, Brunsvig PF, Plessen Von C, Hjelde HH, Garpestad OK, Bailey A, Bremnes RM. Norwegian Lung Cancer Study Group (2007) Vinorelbin/carboplatin vs gemcitabine/carboplatin in advanced NSCLC shows similar efficacy, but different impact of toxicity. Br J Cancer 97: 283-289.
18. Hjermstad MJ, Fayers PM, Bjordal K, Kaasa S (1998) Health-related quality of life in the general Norwegian population assessed by the European Organization for Research and Treatment of Cancer Core Quality-of-Life Questionnaire: The QLQC30 (+3). J Clin Oncol 16: 1188-1196.
19. Jassem J, Ramlau R, Karnicka-Modkowska H, Krawczyk K, Krzakowski M, Zatloukal P, Lemarie E, Hartmann W, Novakova L, O'Brien M, Depierr A (2001) A multicenter randomized phase II study of oral vs. intravenous vinorelbin in advanced non-small-cell lung cancer patients. Ann Oncol 12: 1375-1381.
20. Kaasa S, Hjermstad MJ, Jordhøy MS, Wisløff F, Loge JH (1998) Compliance in quality of life data: A Norwegian experience. Stat Med 17: 623-632.
21. Kaasa S, Thorud E, Høst H, Lien HH, Lund E, Sjølie I (1988) A randomized study evaluating radiotherapy versus chemotherapy in patients with inoperable non-small cell lung cancer. Radiother Oncol 11: 7-13.
22. Kirkpatrick JP, van der Kogel AJ, Schultheiss TE (2010) Radiation dosevolume effects in the spinal cord. Int J Radiat Oncol Biol Phys 76: S42-S49.
23. Krzakowski M, Provencio M, Utracka-Hutka B, Villa E, Codes M, Kuten A, Henke M, Lopez M, Bell D, Biti G, Merimsky O, Beorchia A, Riggi M, Caux N-R, Pouget J-C, Dubray B, David P (2008) Oral vinorelbin and cisplatin as induction chemotherapy and concomitant chemoradiotherapy in stage III non-small cell lung cancer: Final results of an international phase II trial. J Thorac Oncol 3: 994-1002.
24. Lally BE, Wagner H, Langer C, Thomas CR (2011) Assessing patient accrual to cooperative group lung cancer trials: Why are rates disappointing? J Thorac Oncol 6: 1971-1973.
25. Lara PN, Higdon R, Lim N, Kwan K, Tanaka M, Lau DH, Wun T, Welborn J, Meyers FJ, Christensen S, O'Donnell R, Richman C, Scudder SA, Tuscano J, Gandara DR, Lam KS (2001) Prospective evaluation of cancer clinical trial accrual patterns: Identifying potential barriers to enrollment. J Clin Oncol 19: 1728-1733.
26. Lau DH, Crowley JJ, Gandara DR, Hazuka MB, Albain KS, Leigh B, Fletcher WS, Lanier KS, Keiser WL, Livingston RB (1998) Southwest Oncology Group phase II trial of concurrent carboplatin, etoposid, and radiation for poor-risk stage III non-small-cell lung cancer. J Clin Oncol 16: 3078-3081.
27. Le Chevalier T, Arriagada R, Quoix E, Ruffie P, Martin M, Douillard JY, Tarayre M, Lacombe-Terrier MJ, Laplanche A (1994) Radiotherapy alone versus combined chemotherapy and radiotherapy in unresectable non-small cell lung carcinoma. Lung Cancer 10(Suppl 1): S239-S244.
28. Lester JF, Macbeth FR, Toy E, Coles B (2006) Palliative radiotherapy regimens for non-small cell lung cancer. Cochrane Database Syst Rev (4): Doi:10.1002/14651858.CD002143.pub2.
29. Moher D, Hopewell S, Schulz KF, Montori V, Gøtzsche PC, Devereaux PJ, Elbourne D, Egger M, Altman DG. Consolidated Standards of Reporting Trials Group (2010) CONSORT 2010 Explanation and elaboration: Updated guidelines for reporting parallel group randomised trials. J Clin Epidemiol 63: E1-e37.
30. Nawrocki S, Krzakowski M, Wasilewska-Tesluk E, Kowalski D, Rucinska M, Dziadziuszko R, Sowa A (2010) Concurrent chemotherapy and short course radiotherapy in patients with stage IIIA to IIIB non-small cell lung cancer not eligible for radical treatment: Results of a randomized phase II study. J Thorac Oncol 5: 1255-1262.
31. O'Rourke N, Roqué I, Figuls M, Farré Bernadó N, Macbeth F (2010) Concurrent chemoradiotherapy in non-small cell lung cancer. Cochrane Database Syst Rev (6): Doi:10.1002/14651858.CD002140.pub3.
32. Osoba D, Bezjak A, Brundage M, Zee B, Tu D, Pater J. Quality of Life Committee of the NCIC CTG (2005) Analysis and interpretation of health-related quality-of-life data from clinical trials: Basic approach of The National Cancer Institute of Canada Clinical Trials Group. Eur J Cancer 41: 280-287.
33. Osoba D, Rodrigues G, Myles J, ZEE B, PATER J (1998) Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 16: 139-144.
34. Pijls-Johannesma M, Houben R, Boersma L, Grutters J, Seghers K, Lambin P, Wanders R, De Ruysscher D (2009) High-dose radiotherapy or concurrent chemo-radiation in lung cancer patients only induces a temporary, reversible decline in QoL. Radiother Oncol 91: 443-448.
35. Plessen Von C, Bergman B, Andresen O, Bremnes RM, Sundstrom S, Gilleryd M, Stephens R, Vilsvik J, Aasebo U, Sorenson S (2006) Palliative chemotherapy beyond three courses conveys no survival or consistent quality-of-life benefits in advanced non-small-cell lung cancer. Br J Cancer 95: 966-973.
36. Plessen Von C, Strand T-E, Wentzel-Larsen T, Omenaas E, Wilking N, Sundstrom S, Sorenson S (2008) Effectiveness of third-generation chemotherapy on the survival of patients with advanced non-small cell lung cancer in Norway: A national study. Thorax 63: 866-871.
37. Rodrigues G, Macbeth F, Burmeister B, Kelly K-L, Bezjak A, Langer C, Hahn C, Movsas B (2012) Consensus statement on palliative lung radiotherapy: Third international consensus workshop on palliative radiotherapy and symptom control. Clin Lung Cancer 13: 1-5.
38. Schild SE, Stella PJ, Geyer SM, Bonner JA, McGinnis WL, Mailliard JA, Brindle J, Jatoi A, Jett JR. North Central Cancer Treatment Group (2003) The outcome of combined-modality therapy for stage III non-small-cell lung cancer in the elderly. J Clin Oncol 21: 3201-3206.
39. Sundstrøm S, Bremnes R, Aasebø U, Aamdal S, Hatlevoll R, Brunsvig P, Johannessen DC, Klepp O, Fayers PM, Kaasa S (2004) Hypofractionated palliative radiotherapy (17 gy per two fractions) in advanced non-small-cell lung carcinoma is comparable to standard fractionation for symptom control and survival: A national phase III trial. J Clin Oncol 22: 801-810.
40. Sundstrøm S, Bremnes RM, Brunsvig P, Aasebø U, Kaasa S, Norwegian Lung Cancer Study Group (2006) Palliative thoracic radiotherapy in locally advanced non-small cell lung cancer: Can quality-of-life assessments help in selection of patients for short- or long-course radiotherapy? J Thorac Oncol 1: 816-824.
41. Takigawa N, Kiura K, Segawa Y, Hotta K, Tamaoki A, Tokuda Y, Nagata T, Watanabe K, Gemba K, Moritaka T, Horita N, Takeda H, Okimoto N, Takemoto M, Matsuo K, Shinkai T, Tabata M, Ueoka H, Kanazawa S, Tanimoto M (2011) Benefits and adverse events among elderly patients receiving concurrent chemoradiotherapy for locally advanced non-small cell lung cancer: Analysis of the Okayama Lung Cancer Study Group trial 0007. J Thorac Oncol 6: 1087-1091.
42. Wagner H (2008) Just enough palliation: Radiation dose and outcome in patients with non-small-cell lung cancer. J Clin Oncol 26: 3920-3922.
43. Wang XS, Fairclough DL, Liao Z, KOMAKI R, Chang JY, Mobley GM, Cleeland CS (2006) Longitudinal study of the relationship between chemoradiation therapy for non-small-cell lung cancer and patient symptoms. J Clin Oncol 24: 4485-4491.
44. Werner-Wasik M, Paulus R, Curran WJ, Byhardt R (2011) Acute esophagitis and late lung toxicity in concurrent chemoradiotherapy trials in patients with locally advanced non-small-cell lung cancer: Analysis of the radiation therapy oncology group (RTOG) database. Clin Lung Cancer 12: 245-251.
45. World Health Organization (1979) WHO Handbook for Reporting Results of Cancer Treatment. WHO offset publication No. 48WHO: Geneva, Switzerland.